All lobbying filings

FORBES-TATE

Lobbying for NOVARTIS, INC. · Multinational biopharmaceutical company

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Health Issues

Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.

Medicare/Medicaid

Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.

Trade (domestic/foreign)

Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.

Budget/Appropriations

Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.

Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.

Taxation/Internal Revenue Code

Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.

Bills named in this filing 4

H.R. 1672
Maintaining Investments in New Innovation Act
H.R. 3037
Access to Breast Cancer Diagnosis Act of 2025
S. 1500
Access to Breast Cancer Diagnosis Act of 2025
S. 832
EPIC Act of 2025

Foreign interests disclosed 1

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

NOVARTIS INTERNATIONAL AG

Switzerland · Basel · owns 100% of the client · contributed $0

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.